OBI-992

OBI Pharma, Inc · Phase 1 active Small molecule

At a glance

Generic name	OBI-992
Sponsor	OBI Pharma, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OBI-992 CI brief — competitive landscape report
OBI-992 updates RSS · CI watch RSS
OBI Pharma, Inc portfolio CI